INTEGRAGEN COMPLETES €8 MILLION FINANCING TO PROGRESS GENETIC TESTS FOR COMPLEX DISEASES

A A

IntegraGen, a company focused on the development and delivery of genetic tests for complex diseases has announced the successful closing of its second financing round raising €8 million ($9.6 million), which brings the total capital raised by IntegraGen to date to €20 million ($24 million). The international syndicate of investors comprising both existing and new investors participating included CDC Entreprises Innovation, AGF Private Equity, Bioam, SGAM Alternative Investments, and Baytech Venture Capital.

Biotech Intelligence (http://www.biotech-intelligence.com/html/html/7e094f0824d5294c511d4517b244f11a.html)